title: The effect of systemic anti-tumor necrosis factor-alpha treatment on Porphyromonas gingivalis infection in type 2 diabetic mice.
abstract: OBJECTIVE
  Diabetes mellitus and periodontal disease are two common chronic diseases that have long been thought to be biologically linked. Overexpression of tumor necrosis factor alpha (TNF-alpha) is thought to contribute to this bidirectional inter-relationship. This study examined the effect of anti-TNF-alpha antibody treatment on Porphyromonas gingivalis infection in diabetic mice.
  
  
  METHODS
  In C57BL/6 (normal) and KKAy (diabetic) mice, the area adjacent to the periosteum at a point on the skull midway between the ears was inoculated with P. gingivalis. At 24h after the inoculation, the mice in the test group were treated with rat anti-murine TNF-alpha intravenously, while the control group received non-immunized rat IgG. TNF-alpha, IL-6, and fasting blood glucose levels in the mice were measured on day 3.
  
  
  RESULTS
  Anti-TNF-alpha antibody treatment improved the host response to P. gingivalis and was associated with reduced serum TNF-alpha, IL-6, and fasting blood glucose levels in the KKAy mice. Anti-TNF-alpha antibody treatment also decreased the lesion size at the P. gingivalis inoculation.
  
  
  CONCLUSIONS
  Our results suggest that TNF-alpha plays a role in the two-way relationship between P. gingivalis infection and diabetes mellitus. Anti-TNF-alpha antibody treatment may improve the host response to P. gingivalis infection and glycemic control in diabetes mellitus.
authors.affiliation: Nihon University Graduate School of Dentistry, Tokyo, Japan.
authors.forename: Mayuko
authors.initials: M
authors.lastname: Takano
authors.forename: Rieko
authors.initials: R
authors.lastname: Nishihara
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Sugano
authors.forename: Kazuma
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamada
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Takane
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Fujisaki
authors.forename: Koichi
authors.initials: K
authors.lastname: Ito
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000627:therapeutic use*; D016866:Bacteroidaceae Infections / Q000150:complications / Q000382:microbiology / Q000628:therapy*; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D010518:Periodontitis / Q000628:therapy*; D016966:Porphyromonas gingivalis; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000097:blood / Q000276:immunology
chemical_list: D000906:Antibodies; D001786:Blood Glucose; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha